Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

This Growth Stock Rose Last Week. Is It Still a Buy?

TheMotleyFool

0 0

This Growth Stock Rose Last Week. Is It Still a Buy?: https://g.foolcdn.com/editorial/images/704981/gettyimages-637370768.jpg

Shares of Illumina (NASDAQ: ILMN) rose 8% last week and added another 4% on Monday, reaching the stock's highest point since mid-August, on news that the company has developed a speedier gene-sequencing machine.

Illumina stock is still down more than 45% this year and the company has had its share of headaches, but I see it as a great long-term bargain right now.

Shares of Illumina trade for roughly 40 times earnings and have a price-to-sales ratio of 6.6, both of which may seem high, until you consider that the biotech has huge growth potential and has increased revenue by 4,526% over the past 10 years.

Source Fool.com

Like: 0

ILMN

Share